Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in,...
Main Authors: | Samit Chatterjee PhD, Wojciech G. Lesniak PhD, Sridhar Nimmagadda PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-07-01
|
Series: | Molecular Imaging |
Online Access: | https://doi.org/10.1177/1536012117718459 |
Similar Items
-
Development of [F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide
by: Wojciech G. Lesniak PhD, et al.
Published: (2019-06-01) -
Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060
by: Takehiro Tozuka, MD, et al.
Published: (2024-04-01) -
Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
by: Yulin Wan MS, et al.
Published: (2020-08-01) -
Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
by: Jennifer Strong, BS, et al.
Published: (2025-02-01) -
Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
by: Tara Davidson, MD, et al.
Published: (2022-07-01)